Cellectis SA named Elsy Boglioli as COO after the retirement of Mathieu Simon as executive vice president and COO.
Boglioli previously served as executive vice president of strategy and corporate development.
Simon served as Cellectis' executive vice president since 2012 and as COO since 2013. He was also a board member of the company. Simon was appointed interim chief medical officer of the company in October 2017, but was later replaced by Stéphane Depil.
Paris-based Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells.
